SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer [0.03%]
SACI-IO HR+：在激素受体阳性/HER2阴性转移性乳腺癌患者中评估sacituzumab govitecan联合或不联合pembrolizumab的II期随机试验
A C Garrido-Castro,S E Kim,T Li et al.
A C Garrido-Castro et al.
Background: Sacituzumab govitecan (SG), a TROP2-directed topoisomerase I-inhibitor (TOP1i) antibody-drug conjugate, is approved for chemo-refractory hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast ca...
Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial [0.03%]
贝可妥尤单抗治疗复发/转移性鼻咽癌（Magic-M001）：一项多中心、随机对照试验
F Han,Y Q Xiang,X H Wang et al.
F Han et al.
Background: Patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) had limited treatment option and dismal prognosis after failure to programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhib...
ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word [0.03%]
ctDNA指导的II期结直肠癌术后辅助治疗研究：前进一步，仍需更多探索
N Tarazona,A Parikh
N Tarazona
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation [0.03%]
基于提示的环境人工智能在自动化多学科肿瘤委员会记录中的应用
R Philips,A Mahajan,L Estephan et al.
R Philips et al.
Background: Tumor board documentation is challenging due to complexity of multidisciplinary input. Ambient artificial intelligence (AI) for medical dictation uses generative methods to summarize voice data. Strategic prom...
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults [0.03%]
肥胖且未患糖尿病成人使用GLP-1受体激动剂与癌症风险的关系
A H-C Hsu,P T Ramirez,Y-H Chang et al.
A H-C Hsu et al.
Background: Recent data show that glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with decreased cancer incidence in diabetic and obese patients. However, there have been no studies exclusively invest...
Matthieu Roulleaux Dugage,François-Xavier Danlos,Julien Vibert et al.
Matthieu Roulleaux Dugage et al.
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer [0.03%]
基于多模态人工智能的阿比特龙在极高危非转移性前列腺癌患者中的疗效预测：STAMPEDE两项III期临床试验
C T A Parker,H-C Huang,E Grist et al.
C T A Parker et al.
Background: Long-term androgen deprivation therapy (LT-ADT) with radiotherapy is standard-of-care for high-risk localized prostate cancer, with abiraterone added for clinically very high-risk disease. Given the toxicity a...
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer [0.03%]
绝经前激素受体阳性早期乳腺癌患者行辅助化疗的最终结果：SOFT和TEXT三期临床试验
P A Francis,O Pagani,G F Fleming et al.
P A Francis et al.
Background: The SOFT trial found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. SOFT and TEXT combined analysis showed a sig...
Chemotherapy for patients with circulating tumour DNA positive, stage II colon cancer (CIRCULATE) - an AIO / ABCSG trial [0.03%]
II期结肠癌患者循环肿瘤DNA阳性化疗疗效研究（CIRCULATE，AIO/ABCSG临床试验）
G Folprecht,S Stasik,A Reinacher-Schick et al.
G Folprecht et al.
Background: Adjuvant chemotherapy provides limited benefit in unselected stage II colon cancer. Postoperative ctDNA has higher prognostic value than classical clinical markers, with ctDNA positivity indicating an unfavour...
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3 [0.03%]
一项关于恩考芬尼、西妥昔单抗和FOLFIRI与FOLFIRI（贝伐珠单抗联用或不联用）治疗BRAF V600E突变型结直肠癌的随机研究：BREAKWATER 3队列
S Kopetz,J Tabernero,S Lonardi et al.
S Kopetz et al.
Background: Encorafenib + cetuximab (EC) and mFOLFOX6 or irinotecan, leucovorin, and fluorouracil (FOLFIRI) is approved in several countries for BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on results from ...